Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q1 2025
Kiniksa Pharmaceuticals International (KNSA) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 29, 2025
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $138M for the first quarter 2025 (Q1 2025), +73% from a year earlier and +12% from the quarter before. Operating margin was 9.6%, net earnings $8.5M (6.2% of revenue).
Kiniksa Pharmaceuticals International, Q1 2025: revenue $138M (+72% year over year), operating margin 9.6%, net earnings $8.5M, operating cash flow $22.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $138M | +12% | +73% |
| Operating profit | $13.3M | — | — |
| Net earnings | $8.5M | — | — |
| Operating cash flow | $22.3M | +19% | +460% |
| Free cash flow | $22.2M | +20% | +469% |
What changed
Revenue was $137.8M in Q1 2025, up 73% year over year and up 12% from the previous quarter.
Operating profit was $13.3M, a 9.6% margin (up 30.3 points year over year). Total costs grew 29% against revenue growth of 73%. The fastest-growing cost line was Other operating costs (+111%). Net earnings were $8.5M. The effective tax rate was 45.1%.
Operating cash flow was $22.3M (up 460% year over year), 261% of net earnings. Non-cash charges added back $345K of depreciation and amortization and $7.7M of share-based compensation. Working capital and other items added $5.7M. Capital expenditures of $99K left free cash flow of $22.2M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the first quarter 2025?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $138M for the first quarter 2025 (Q1 2025), +73% from a year earlier and +12% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the first quarter 2025?
Operating profit was $13.3M (9.6% of revenue) and net earnings $8.5M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.